Previous 10 | Next 10 |
2023-08-18 07:27:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting the final day of trading this week with a dive into the biggest pre-market stock movers for Friday! Moving stocks this morning are earnings reports, clinical trial res...
2023-08-03 09:42:01 ET Avalo Therapeutics press release ( NASDAQ: AVTX ): Q2 GAAP EPS of -$0.59 beats by $0.21 . Revenue of $0.64M (-37.9% Y/Y) beats by $0.14M . For further details see: Avalo Therapeutics GAAP EPS of -$0.59 beats by $0.21, revenue of $0....
Announced AVTX-002 (quisovalimab) did not meet its primary endpoint in its Phase 2 PEAK Trial in non-eosinophilic asthma, however AVTX-002 significantly reduced serum LIGHT levels for study duration indicating strong target engagement Disclosed cash of approximately $6.3 million as of June ...
WAYNE, Pa. and ROCKVILLE, Md., July 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will participate in the SVB Securities Therapeutics Forum being held Tuesday, July 11th – We...
2023-06-27 07:34:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start the day with a breakdown of the biggest pre-market stock movers worth watching on Tuesday! Moving stocks this morning are delisting notices, clinical trial results...
2023-06-26 12:52:19 ET Gainers: Benitec Biopharma ( BNTC ) +76% . MoonLake Immunotherapeutics ( MLTX ) +68% . Paltalk ( PALT ) +27% . Whole Earth Brands ( FREE ) +26% . Shengfeng Development Limited ( SFWL ) +26% . Belite Bio...
2023-06-26 10:08:32 ET Gainers: MoonLake Immunotherapeutics ( MLTX ) +69% . Chemomab Therapeutics ( CMMB ) +33% . Acelyrin ( SLRN ) +22% . ORIC Pharmaceuticals ( ORIC ) +15% . Losers: Avalo Therapeutics ( AVTX ) -85% . Fi...
2023-06-26 08:22:19 ET Avalo Therapeutics ( AVTX ) -89% announces topline data from phase 2 PEAK trial for AVTX-002 (quisovalimab) in patients with non-eosinophilic asthma. FibroGen ( FGEN ) -76% late-stage trial for lung disease candidate fails . Lulu's Fa...
AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo, although positive trends were observed among a sub-population of patients with elevated baseline serum LIGHT levels AVTX-002 significantly reduced serum LIGHT levels for stud...
WAYNE, Pa. and ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 11:00 a.m. ET at the...
News, Short Squeeze, Breakout and More Instantly...
Avalo Therapeutics Inc. Company Name:
AVTX Stock Symbol:
NASDAQ Market:
Avalo Therapeutics Inc. Website:
WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. “We are thrilled to have Mittie join and grow our leadership team at an exciting...
Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Ava...
2024-07-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...